Human noroviruses (NoVs) are the main etiological agents of acute gastroenteritis 26 worldwide. While NoVs are highly diverse (more than 30 genotypes have been 27 detected in humans), during the last 40 years most outbreaks and epidemics have been 28 caused by GII.4 genotype strains, raising questions about their persistence in the 29 population. Among other potential explanations, immune evasion is considered to be 30 a main driver for their success. In order to study antibody recognition and evasion in 31 detail, we have analyzed a conformational epitope recognized by a monoclonal 32 antibody (3C3G3) by phage display, site-directed mutagenesis and surface plasmon 33 resonance. Our results show that the predicted epitope is composed of eleven amino 34 acids within the P domain: P245, E247, I389, Q390, R397, R435, G443, Y444, P445, 35 N446, and D448. Only two of them, R397 and D448, differ from the homologous 36 variant (GII.4 Den-Haag_2006b) and from a previous variant (GII.4 VA387_1996) 37 which is not recognized by the antibody. A double mutant derived from the 38 VA387_1996 variant containing both changes Q396R and N447D is recognized by 39 the 3C3G3 monoclonal antibody, confirming the participation of these two sites in the 40 epitope recognized by this antibody. Furthermore, a single change, Q396R, is able to 41 modify the HBGA recognition pattern. These results provide evidence that the epitope 42 recognized by the 3C3G3 antibody is involved in the virus-host interactions both at 43 the immunological, as well as at the receptor levels. 44 KEY WORDS: Norovirus, GII.4 genotype, epitope, monoclonal antibody, virus-host 45 interaction, viral variant, antibody escape, receptor 46 on July 13, 2016 by University of Liverpool Library http://jvi.asm.org/ 47 IMPORTANCE 48 Human noroviruses are the main cause of viral diarrhea worldwide in people of all 49
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Noroviruses (NoVs) are the predominant etiological agents of acute gastroenteritis 62 worldwide, causing both outbreaks and sporadic cases (1-3). NoVs have become in 63 many countries the main cause of infantile gastroenteritis since the introduction of 64 rotavirus vaccines (4-7), and they have also been recognized globally as the main 65 cause of associated foodborne diseases (8, 9) . 66
NoVs belong to the Caliciviridae family, and currently they are classified into 6 67 genogroups (GI-GVI) (10) subdivided into more than 30 genotypes based on the 68 capsid protein sequence diversity. That notwithstanding, most human NoV infections 69 are caused by genogroups GI and GII. Furthermore, in the last two decades genotype 70 GII.4 has been the causative agent of >95% of NoV gastroenteritis outbreaks, with 71 globally distributed epidemic viral variants emerging every 2-3 years (11, 12) . 72
NoVs are small non-enveloped viruses with a non-segmented single-stranded 73 positive-sense RNA genome, which encodes the viral structural and non-structural 74
proteins in three open reading frames (ORFs). ORF1 encodes the six non-structural 75 proteins, including the viral protease and the RNA-dependent RNA polymerase 76 (RdRp), while ORF3 encodes a small basic protein, VP2, which interacts with the 77 VP1 and stabilizes the virion (13). ORF2 encodes the major structural protein VP1, 78 which is further organized into the N-terminal (N), the shell (S), and the protruding 79 (P) domains. The P domain can be further divided into two subdomains, P1 and P2 80 (14) . The P1 subdomain forms the anchoring portion of the P dimer, connecting it to 81 the S domain and promoting the stability of the viral particle, while the P2 subdomain 82 is exposed on the surface of the capsid protein and is the most variable region of the 83 virus (11). Both the main epitopes for immunorecognition, as well as the histo-blood 84 group antigen (HBGA) binding domains, reside within this P2 subdomain. The 85 on July 13, 2016 by University of Liverpool Library http://jvi.asm.org/ Downloaded from emergence and accumulation of mutations along the P2 subdomain is the main driver 86 of evolution for GII.4 strains, and results in new epidemic strains with altered 87 antigenicity and HBGA binding properties (15) (16) (17) (18) . 88 GII.4 genotypes associated with the majority of NoV pandemics have been GII.4 89 US1995_1996, Farmington_Hills_2002, GII.4 Hunter_2004, GII.4 Den Haag_2006b, 90 GII.4 New Orleans_2009, and most recently GII.4 Sydney_2012. Of these six 91 pandemic strains, it has been postulated that the first four are the result of the 92 mutational evolution of the P domain capsid, whereas the two most recent variants 93 display additional recombination events between ORF1 and ORF2 (12, 19) . 94
Despite recent advances in norovirus culture in vitro (20) , the historical lack of an in 95 vivo model (which mimics the disease) and of a reproducible in vitro replication 96 system have hampered the study of NoVs including a definitive explanation to the 97 evolutionary success of GII.4 strains. Despite these challenges, several alternatives 98 and surrogate systems have been successfully applied to the study of the 99 immunogenicity and receptor binding properties of NoV strains and their variants. 100
Virus-like particle (VLP) expressed in mammalian or insect cells (21) and P particles 101 expressed in E. coli (22) show similar structural properties to the native virus, 102 maintain the antigenic properties and HBGA binding ability, and their use has led to 103 the identification of several epitopes and HBGA binding domains (15, (23) (24) (25) (26) . 104
In order to further characterize the impact of NoV GII.4 evolution on immune 105 evasion, we analyzed the functionality of the epitope recognized by a monoclonal 106 antibody (3C3G3) directed against a NoV GII.4 strain, using phage display and site-107 directed mutagenesis. The epitope recognized is composed of eleven amino acids, two 108 6 of them, R397 and D448, being implicated in the folding of the epitope and in the 109 recognition patterns for different HBGAs. 110
111

MATERIALS AND METHODS 112
Expression and purification of norovirus virus-like particles (NoV VLPs) 113
VLPs of NoV strains GI.1 Norwalk, GII.3, GII.4_1999 (v0), GII.4_2004 (v2) and 114 GII.4 Den Haag_2006b were expressed in insect cells after infection with 115 recombinant baculoviruses, as previously described (15). 116 117 Expression and purification of recombinant NoVs P particles and P domains 118 P particles from NoV GI.1 Norwalk strain, GII.9 VA207 strain and GII.4 variants 119 VA387_1996, Den Haag_2006b and Sydney_2012, as well as five mutants of the 120 VA387_1996 variant (M1 to M5, see below) were produced and purified in E. coli 121 BL21 as previously described (27). GII.9 VA207 synthetic gene was purchased as a 122 synthetic gene (GeneArt, Invitrogen). The Den Haag_2006b P particle was subcloned 123 from a previous VP1 construction available in our laboratory (28) using the primers 124 P524 and P590 previously described (22), and the GII.4 Sydney_2012 variant was 125 cloned from a clinical sample using P-Sydney forward 126 (5'GCACGGATCCTCAAGAACTAAACCATTCTCTG3') and reverse 127 (5'GCATGCGGCCGCTTAGCAAAAGCAATCGCCACGGCAATCGCATACTGC 128 ACGTCTACGCCCCGTTCC3') primers. The P domain of the GII.4 Apeldoorn_2007 129 strain was also produced and purified as previously described (28). This construction 130 is referred to as P domain and not P particle because it lacks the cysteine rich peptide 131 that stabilizes the formation of P particles. 132 injection, mouse spleen lymphocytes were fused with Sp2/0-Ag14 myeloma cells and 144 hybridomas were screened by ELISA and subcloned by limiting dilution. One of the 145 growing hybridomas produced an anti-GII.4_2006b VLP mAb (3C3G3) which was 146 purified using HiTrap protein A sepharose columns (GE Healthcare). Two previously 147 obtained and characterized monoclonal antibodies were also used in the present study: 148 the anti-v0.8 mAb raised against the pre-epidemic GII.4 v0_2000 variant, and the 149 anti-v2.5 mAb raised against the GII.4 v2_2004 variant (15). Two polyclonal antisera 150 were also utilized in the present study. These were obtained by immunizing rabbits 151 following standard methods, either with GII4 VA387_1996 P particles (P-pAb) or 152 with a mixture of VLPs GII.4 v0_2000, GII.4 v2_2004 and GII.3 (HPA-pAb). 153 154 Characterization of antibodies by ELISA 155 on July 13, 2016 by University of Liverpool Library http://jvi.asm.org/
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The 96-well microtiter plates (Corning, NY) were coated with the different VLP 156 variants, P particles or P domain (see above) at 1 µg/ml in carbonate/bicarbonate 157 buffer (pH 9.2) and incubated overnight at 4ºC. Plates were blocked by incubating 1 h 158 at 37ºC in PBS 0.05% Tween (PBST) with 3% BSA. The primary antibodies (anti-159 v0.8 mAb, anti-v2.5 mAb, 3C3G3 mAb, P-pAb and HPA-pAb were added to the 160 coated plates at two fold dilutions starting at 1/1,000 until 1/128,000 dilution in PBST 161 containing 1% BSA. Binding was detected with either HRP-conjugated anti-mouse 162 IgG at 1/4,000 or anti-rabbit IgG at the same dilution (Santa Cruz Biotechnology) as 163 appropriate. The reactions were developed by the addition of OPD (o-164 phenylenediamine dihydrochloride, Sigma) and stopped after 10 min of incubation 165 with 3 M H 2 SO 4 . Absorbance was measured at 492 nm in a microplate reader 166
Multiskan Spectrum (Thermo Fisher Scientific, Vantaa, Finland). Assays were 167 performed in triplicate and negative and blank controls were included. The mean 168 value of negative controls (without primary antibody) plus 3 SDs was used as the cut-169 off value. 170
Saliva binding blocking assay 171
Microtiter plates (Corning, NY) were coated with saliva from one secretor positive 172 donor diluted 1/500 in carbonate/bicarbonate buffer (pH 9.2), and incubated 37ºC for 173 1 h and at 4ºC overnight. Plates were washed three times with PBST and blocked with 174 PBS containing 3% BSA for 1 h at 37ºC. The GII.4 2006b P particles (1 µg/ml) were 175 incubated 1 h with serial dilutions of the 3C3G3 mAb in PBST at 37ºC. The mixture 176 was added to the coated plate and incubated for 1 h at 37ºC. After three washes, the P-177 pAb was added at a dilution of 1/1,000. Finally, a HRP-conjugated anti-rabbit at 178 196 Unbound phages were removed by washing with 0.01% TBST. The 3C3G3 mAb-197 bound phages were eluted with 100 μl of glycine (0.2 M glycine-HCl, pH 2.2) 198 containing 1 mg/ml of BSA and then neutralized with 15 μl of Tris-HCl 1 M pH 9.1. 199
The eluted phages were amplified and purified to be used for subsequent rounds of 200 selection and to infect E. coli ER2738 for amplification and titration. In the second 201 and third rounds of panning, the stringency of washing was augmented by increasing 202 the number of washes and the amount of Tween-20, in consecutive rounds. 203
After three rounds of panning-elution selection, individual positive clones were 204 picked up from LB/IPTG/Xgal plates, amplified and submitted for DNA sequencing. 205 on July 13, 2016 by University of Liverpool Library http://jvi.asm.org/
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The primer used for sequencing was 96gIII (5′-CCCTCATAGTTAGCGTAACG-3′), 206 provided by the kit. The sequences coding 7 amino acids were identified and used to 207 predict the epitope. 208 209
Epitope modeling 210
Conformational modeling of the epitope was carried out using the Pepitope server 211 (29). The crystal structure of the NoV GII.4 VA387_1996 strain was used as the 212 model to localize the epitope recognized by mAb 3C3G3 (PDB id: 2OBR). The 213
Modeller (http://salilab.org/modeller/) program (version 9.15) was used for homology 214 and comparative modeling of three-dimensional protein structures (30). We used the 215 GII.4 VA387_1996 strain structure as the template (PDB id: 2OBR) and provided an 216 adequate alignment with the sequences of the different mutants M1 to M5 (see 217 below). The Modeller software built the required number of models of the target and 218 estimated the quality parameters of the models. The model with the best dope score 219 was chosen for each mutant. The structures were visualized with the Pymol (The 220
PyMol Molecular Graphics System, Version 0.99, Schrodinger, LLC) program. 221 222
Site-directed mutagenesis 223
To confirm the amino acid residues forming part of the 3C3G3 epitope, the GII.4 224 VA387_1996 strain (not recognized by the antibody) was used as a scaffold to 225 incorporate the amino acids present in the predicted epitope. Five mutants were 226 constructed by introducing the following mutations into the GII.4 VA387_1996 227 sequence: M1 (Q396R); M2 (N447D); M3 (NN-393, 394 STT); M4 (M1+M2); and 228 M5 (M1+M2+M3) (Figure 1 ). The GeneArt site-directed mutagenesis system 229 on July 13, 2016 by University of Liverpool Library http://jvi.asm.org/ Downloaded from (Thermo Fisher) was applied following the manufacturer's instructions to incorporate 230 the mutations. The primers utilized to create the mutants are listed in Table 1. M1 and  231 M2 were produced in one step, but M3 was constructed in two steps using first the 232 MUT_3_1_FW and MUT_3_1_RV primers and then the MUT_3_2_FW and 233 MUT_3_2_RV in a second mutagenesis reaction. The M4 construction (double 234 mutant incorporating M1 and M2) was made using the M1 construction as the 235 template and incorporating the M2 mutation afterwards. To create the M5 mutant, the 236 M3 construction was used as template using primers MUT_1_3_FW and 237 MUT_1_3_RV to incorporate M1 without changing the M3 mutation that was already 238 present, followed by the addition of the M2 mutation. 239
Transformants were analyzed by PCR and sequencing. Positive transformants were 240 transferred to the E.coli BL21 strain GroES/EL and mutant P particles were produced 241 and purified as previously described (27). 242 243
Surface plasmon resonance (SPR) 244
The binding ability of P particles (GII.4 VA387_1996, M1, M2, M3, M4, M5 and 245 Den Haag_2006b) to three different mAbs (3C3G3, anti-V0.8 and anti-V2.5) was 246 tested by Surface Plasmon Resonance (SPR) using a Biacore T100 instrument 247 (Biacore, GE Healthcare). An anti-His antibody (Clontech) was immobilized on the 248 surface of CM5 chips (GE Healthcare) and used as a capture antibody for P particles. 249
Immobilization was achieved using the Amine Coupling Kit (GE Healthcare). Briefly, 250 5000 anti-His mAb resonance units (RU) were immobilized in channel 2 leaving 251 channel 1 as a reference. Each P particle was captured flowing a solution of 100 252 µg/ml for 100 seconds at a flow rate of 5 µl/min in HBS-EP + buffer (GE Healthcare) The binding of P particles to five different neoglycoproteins (Table 2) Microtiter plates (Corning, NY) were coated with the different neoglycoconjugates at 270 1 µg/ml in carbonate/bicarbonate buffer (pH 9.2), and incubated 37ºC for 1 h and at 271 4ºC overnight. Plates were washed three times with PBST and blocked with PBS 272 containing 3% BSA for 1 h at 37ºC. The P particles were added at 1 µg/ml in PBST 273 and the plates were incubated 90 min at 37ºC. After three washes, the P-pAb was 274 added to the plates at a dilution of 1/1,000. Binding was detected with HRP-275 conjugated anti-rabbit at 1/ 4,000 (Santa Cruz Biotechnology). The With the aim to study the immunogenicity and binding ability of different NoV strains 290 to several HBGAs a total of ten P particles were produced, one corresponding to the 291 GI.1 Norwalk genotype, four corresponding to different GII NoVs (GII.9 VA207 292 strain, GII4 VA387_1996 strain, GII.4 Den Haag_2006b strain and GII4 293 Sydney_2012 strain), and the remaining obtained by site-directed mutagenesis of the 294 GII.4 VA387_1996 P particle (M1 to M5). All the proteins showed a molecular 295 weight close to the expected one (36 kDa), but with small differences. The GII4 296 VA387_1996 variant showed a typical duplet band for this strain (22, 27) . This duplet 297 was also present in the M1 (Q396R) mutant. The M2 mutant (N447D) migrated as a 298 single band, as well as did all the other constructions, except the M4 double mutant 299 that displayed a lower mobility in the gel (Figure 2 ). The P particles were further 300 purified by size exclusion chromatography. The results showed that the majority 301 (more than 80%) of the produced proteins formed particles as it can be observed in 302 Figure 3 . The elution time was slightly different for every preparation ranging from 303 37.89 ml (M1) to 40.29 ml (VA387) that corresponds to 1,030 kDa to 870 kDa 304 ( Figure 3 ). All together we were able to produce and purify ten different P particles 305 that were used in ELISA, SPR and binding assays. 306 307
Characterization of mAb by ELISA 308
In order to elucidate the reactivity patterns of each one of the mAbs against different 309
NoV genogroups, genotypes and variants the initial characterization of mAbs 3C3G3, 310 anti-v0.8 and anti-v2.5 was performed by ELISA using a set of NoV antigens (Table 3  311 on July 13, 2016 by University of Liverpool Library http://jvi.asm.org/ Downloaded from and Figure 4) . As a control, the HPA-pAb was utilized. The 3C3G3 antibody 312 recognized only its homologous VLP (GII.4 Den Haag_2006b) and the most closely 313 related GII.4 Apeldoorn_2007 P domain. Surprisingly, it did not recognize the GII.4 314 v2_2004 VLPs and GII.4 VA387_1996 P particle, two different variants within the 315 same genotype. This result is similar to those obtained with the anti-v0.8 and anti-v2.5 316 mAbs. The anti-v0.8 efficiently recognized its homologous GII.4 v0_1999 VLP and 317 the GII.4 VA387_1996 P particle while the anti-v2.5 recognized only its homologous 318 GII.4 v2_2004 VLP and the closer GII.4 2006b antigen, but not the GII.4 319 Apeldoorn_2007 P domain. The HPA polyclonal antibody was able to recognize all 320 the tested antigens except the GI.1 P particles (Table 3 ). These results confirm that the 321 fast evolution of NoV GII.4 variants seem to be driven by the antibody pressure in the 322 host, favoring the emergence of antibody escape variants. 323
324
The 3C3G3 mAb blocks the binding of P particles to saliva 325
The main aim of the present study was to characterize the epitope of a mAb directed 326 to the viral capsid protein to give an explanation on how antibody evasion occurs in 327 NoV GII.4 variants. It was important to know if the 3C3G3 mAb was able to block 328 the binding of NoV to its receptors. For this reason a saliva binding blocking assay 329 was performed, and the results confirmed that the 3C3G3 mAb is able to block the 330 binding of GII.4 Den Haag_2006b P particles in a dose dependent manner to secretor 331 positive saliva ( Figure 5) . Aiming to characterize the epitope recognized by the 3C3G3 mAb the phage display 336 technique followed by site-directed mutagenesis were applied. After three rounds of 337 panning, a consensus sequence of 11 amino acids was obtained. The predicted epitope 338 was formed by the following amino acids: P245, E247, I389, Q390, R397, R435, 339 G443, Y444, P445, N446, and D448 of the GII.4 Den Haag_2006 variant (Figure 1) . 340
Three of these amino acids are within the P2 subdomain (I389, Q390, R397), and the 341 other eight are within the P1 subdomain ( Figure 6 ). 342
To confirm the epitope, site-directed mutagenesis was performed using the P particle 343 of GII.4 VA387_1996 variant as a scaffold. This variant was not recognized by the 344 3C3G3 mAb, and only two residues were different among both proteins in the 345 predicted epitope R397 and D448 (Figure 1) . Five mutants were produced as 346 described in the Material and Methods section (M1 (Q396R); M2 (N447D); M3 (NN-347 393, 394 STT); M4 (M1+M2) and M5 (M1+M2+M3)), and the reactivity of the 348 3C3G3 mAb against the mutants was tested by ELISA. In addition to the mutants, two 349 new P particles were added to the experiment: The GII.4 Den Haag_2006 variant P 350 particles as the positive control and the GII.4 Sydney_2012 variant P particles to 351 evaluate the performance of the antibody towards the newer GII.4 epidemic variant. 352
The ELISA results, summarized in Table 3 and Figure 7A, found GII.4 Sydney_2012 is not recognized by the mAb while it shares the 11 residues of 360 the predicted epitope (Table 4 ). This indicates that other residues not identified in this 361 study might be implicated in the formation of the 3C3G3 epitope. 362
To know if this novel described epitope affects the binding of other GII.4 directed 363 mAbs the reactivity of anti-v0.8 and anti-v2.5 mAbs against the different P particles 364 was also assayed by ELISA. The results show that the anti-v2.5 epitope might be 365 different from the 3C3G3 epitope since none of the mutants were recognized by this 366 mAb ( Figure 7B ). Interestingly this antibody was also independent from the 367 previously described antigenic site B present here in M3 and M5 constructions (15) . 368
In contrast, the anti-v0.8 mAb reacted against each of the mutants, albeit at different 369 levels. This may indicate that the selected residues exert an influence on the folding of 370 the epitope recognized by this antibody since both mutagenized residues are 371 conserved in VA387_1996 and V0_1999 variants (Table 4 ). According to our results 372 this mAb showed a dependence on the antigenic B site as previously described (15). 373 374
Characterization of the 3C3G3 mAb-epitope by surface plasmon resonance 375
To quantify the interaction strength between the tested mAbs and the different P 376 particles recognized by them, a surface plasmon resonance (SPR) approach was 377 applied and affinity constants (KD) were obtained in at least three independent 378 experiments. Of all the interaction pairs, the highest affinity (lowest KD value) was 379 obtained in the 3C3G3-GII4 Deen Hag_2006b interaction pair (Table 3 and Figure  380 8). Although M4 gave higher signal in ELISA ( Figure 7A ), the SPR experiments 381 revealed that the M4 mutant had 6 times higher KD (153 nM) than M5 mutant did (25 382 on July 13, 2016 by University of Liverpool Library http://jvi.asm.org/ Downloaded from nM) (Table 3) . After modeling the structure of the different mutants, using the P 383 domain of VA387_1996 structure as a scaffold (PDB id: 2OBR), we observed that the 384 R397 and the D448 residues probably present different conformations in M4 and M5 385 ( Figures 3C and D) . The M5 model had the D448 anionic carboxylate (RCOO − ) and 386 R397 cationic ammonium (RNH3 + ) closer. This increased the possibility of a saline 387 bridge formation that permitted the 3C3G3 epitope stabilization. 388
389
R397 is involved in HBGAs recognition 390
The binding of the VA387_1996, Den Haag_2006b and Sydney_2012 variants, as 391 well as of the five mutants (M1 to M5) to five different HBGAs (SiLe x , Le x , blood 392 group O (H antigen), blood group A and blood group B) was analyzed in order to 393 study if the residues involved in their immunogenicity also had an impact in their 394 receptor binding. Our results show that there was a change in the recognition pattern 395 between the VA387_1996 and the Den Haag_2006b and Sydney_2012 variants. 396
While the VA387_1996 strain possessed a high binding ability to the SiLe x antigen, 397 the Den Haag_2006b and Sydney_2012 variants did not recognize any of the assayed 398 antigens (Figure 9 ). Interestingly, the M1 incorporating the single mutation Q396R 399 lost its binding ability to the tested HBAs, showing the same recognition pattern as 400 the 2006b and 2012 variants. The M2 mutant maintained a similar binding to SiLe x as 401 did the wild type VA387_1996. M3 Due to the relevance of the antibody escape variants in NoV GII.4 persistence during 407 the last 40 years, we decided to resolve the epitope recognized by the 3C3G3 mAb, 408 which is a binding blocking antibody. The results of the present study shed light on 409
how NoV escapes to antibody neutralization. This antibody was not able to recognize 410 any of the tested antigens by Western Blot, indicating that the target epitope should be 411 conformational. For this reason, a phage display approach was chosen. Of the eleven 412 residues suspected to form part of the epitope (see Results) two of them, R397 and 413 D448, were confirmed to be part of the epitope by site-directed mutagenesis of 414 VA387_1996 P particles. When different P particles were produced, differences in 415 electrophoretic mobility were observed. These differences in the electrophoretic 416 mobility have been previously reported for the VA387 variant and were associated to 417 P particle formation (P dimers versus P particles) (22) and might reveal structural 418 changes. In the present study, all the designed P particles were found to be 419 successfully constructed, with estimated molecular weights ranging from 870 to 1,030 420 kDa. 421
Besides the R397 and D448 residues, another difference between VA387_1996 and 422 Den Haag_2006b sequences was a change involving amino acids 393-395 (STT in the 423 Den Haag_2006b variant and N-N in the VA387_1996 variant). This change was 424 incorporated in the M3 and M5 mutants because they were in the close vicinity of 425 R397. They had been previously described to form an important epitope in GII.4 426 NoVs (15) . Nevertheless, these three residues did not rescue the binding ability of the 427 3C3G3 antibody (M3 was not recognized by 3C3G3), but they helped stabilizing the 428 3C3G3 epitope, since 3C3G3 had 6 times more affinity for M5 than for M4. After the 429 on July 13, 2016 by University of Liverpool Library http://jvi.asm.org/ Downloaded from molecular modeling of the 5 mutants ( Figure 6 ), we could predict the formation of a 430 saline bridge between R397 and D448 only in M5 and not in M4. That could explain 431 the higher stability of the 3C3G3 epitope in M5, while the 393-395 STT residues did 432 not seem to be part of the 3C3G3 epitope themselves. 433
As shown in Table 4 it seems that residues R397 and D448 have been important in the 434 successive GII.4 variants. In order to elucidate if they are part of epitopes recognized 435 by other mAbs raised against different GII.4 variants we also characterized two 436 previously obtained mAbs, anti-v0.8 and anti-v2.5, that were tested against the same 437 antigens and mutants as 3C3G3 mAb. We confirmed by ELISA and SPR that the anti-438 v0.8 was dependent on antigenic site B (393-395 -NN to STT) as previously 439 described (15). The epitope recognized by anti-v0.8 was also affected in the M1 and 440 M2 mutants, indicating that amino acids 397 and 448 might also be implicated in the 441 epitope conformation. Furthermore, the results with all three mAbs showed that there 442 was only cross reactivity between the closer variants, and that none of the more 443 distant variants shared any reactivity (Table 3 ). The anti-v2.5 mAb only recognized 444 the more closely P particle corresponding to the GII.4 Den Haag_2006b variant. All 445 the mutants were made using the VA387_1996 variant as scaffold that is not 446 recognized by this antibody. Only if R397 and D448 were present in its epitope, 447 recognition by this antibody would be recovered. The only conclusion that we can 448 obtain is that these residues might not be part of the anti-v2.5 mAb epitope. 449
These results possess important implications from the evolutionary point of view, 450 since they demonstrate that the mAbs against the older variants do not recognize the 451 newer ones. They explain why the same genotype can produce successive pandemics. 452
Moreover, the HPA-pAb is able to recognize the GI.1 VLPs, but not the GI.1 P 453 on July 13, 2016 by University of Liverpool Library http://jvi.asm.org/ Downloaded from particles, supporting the idea that the cross-reactive epitopes between both NoV 454 genogroups are present only in the shell domain of VP1, which is not present in the P 455 particles (31, 32) . 456
When the 3C3G3 epitope was compared in several NoVs GII.4 variants (Table 4) , the 457 two residues identified in the present study, R397 and D448, were always conserved. 458
All the variants prior to 2004 possessed the combination Q397-N448, and all the 459 variants that emerged since 2006 contain the duplet R397-D448. There was a 460 transition period between 2004 and 2006 where both duplets were present, but always 461 in the same combination. In the VA387_1996 structure and in the structural models of 462 Figure 6 it was observed that these two amino acids were located very close to each 463 other, and in M5 they seemed to interact through a saline bridge. This physical 464 interaction might explain why these two residues were in fixed combinations 465 throughout the different variants. We could hypothesize that these residues might 466 additionally be involved in the stabilization of the P particle itself, not just in the 467 3C3G3 epitope. Indeed, we observed changes in the electrophoretic mobility of the 468 different P particles when these residues were mutagenized within the VA387_1996, 469 M1 and M4 P particles being the most heterogeneous migrating particles. 470
Nevertheless, the Den Haag_2006b and Sydney_2012 variants, which possess the 471 R397-D448 pair, along with the 393-395 STT version of the antigenic site B (that 472 favors the formation of the R397-D448 saline bridge), were more homogenous than 473 was the 1996 variant. 474
It is known that GII.4 noroviruses have strain specific HBGAs recognition patterns 475 (17, 18, 33) . To evaluate whether the 3C3G3 epitope was involved in the interaction 476 with receptors, we analyzed the binding of the different GII.4 P particles to several 477 HBGAs. Our results indicated that the change in R397 seemed to be the key in the 478 on July 13, 2016 by University of Liverpool Library http://jvi.asm.org/ Downloaded from different recognition patterns seen in the newer GII.4 variants compared to those of 479 the older ones. The conclusion reached was that this change might have had an effect 480 on the folding of the fucose-binding pocket that is not in contact with this residue 481 ( Figure 6) . 482
Interestingly, the M4 mutant that includes both substitutions (Q396R and N447D) has 483 an exacerbated binding ability including a high binding to the HSA (negative control). 484
In Table 4 we can observe that this amino acid combination (R396 and D447) is 485 always accompanied with the antigenic site B triplet and not with the duplet as it is 486 present in M4. The combination of the antigenic site B duplet with R396 and D447 487 has not been found in wild-type viruses so far, which may reflect a negative selection 488 process probably due to its impaired binding, as seen with M4 mutant. 489
This was the first time that phage display was applied to study GII.4 NoV epitopes. In 490 previous studies, evolutionary and structural approaches were used to identify 491 putative epitopes including site A (amino acids 296-298) and B (amino acids 393-492 395) (16). These epitopes were confirmed using chimeras between different NoV 493 GII4 variants and monoclonal antibodies (15). A similar approach showed that site A 494 should be formed by amino acids 294, 368 and 372 in addition to 296-298 (17) . It 495 whas also been shown that epitope B had an influence on the changes in the HBGA 496 binding abilities of different GII4 variants (17, 18) . Using the phage display technique 497 we have been able to identify two residues (397 and 448) that were not as exposed as 498 the previously described epitopes, thus making it difficult to predict their relevance 499 after structural analysis. We have shown that these residues play an important role in 500 antibody recognition, HBGA interactions, and that they have evolved from ancestral 501 to modern variants. 502 on July 13, 2016 by University of Liverpool Library http://jvi.asm.org/ Downloaded from Altogether, we were able to study the epitope recognized by the 3C3G3 antibody and 504 have shown that this epitope was implicated in viral host interactions. On the one 505 hand, the two amino acids, R397 and D448, seemed to be involved in the evasion to 
